Thu, Apr 25, 2024
A A A
Welcome Guest
Free Trial RSS pod
Get FREE trial access to our award winning publications
Alternative Market Briefing

Ackman to pursue Allergan acquisition, a new corporate actions model emerges

Tuesday, April 22, 2014

Bailey McCann, Opalesque New York:

As Opalesque recently reported, investors are lining up for activist strategies. Those investors may be interested in the latest news from Pershing Square CEO Bill Ackman who is teaming up with Valeant Pharmaceuticals International Inc. seek to acquire the botox maker, Allergan Inc. The partnership was first reported late yesterday afternoon and marks another high profile bet for the activist who has recently staked out positions on Herbalife and JC Penny.

Valeant owns other well known brands including Bausch & Lomb and focuses heavily on eye-care. According to reports, Valeant has been trying to acquire Allergan for some time, but this acquisition attempt is likely to be hostile. Both companies posted gains in after hours trading.

The New York Times notes that if the bid is successful, a hedge fund teaming up with a corporation could provide a new model for corporate actions. The deal would have to be approved by regulators which are likely to give the transaction close scrutiny given the possibility for conflicts of interest. ......................

To view our full article Click here

Previous Opalesque Exclusives                                  
Previous Other Voices                                               
Access Alternative Market Briefing

 



  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. KKR raises $6.4bn for the largest pan-Asia infrastructure fund[more]

    Laxman Pai, Opalesque Asia: The New York-based global investment firm KKR has raised a record $6.4bn for its second Asia-focused infrastructure fund, underlining investors' continued appetite for private markets. According to a media release from the alternative assets manager, the figure top

  2. Bucking the trend, top hedge fund makes plans for a second SPAC[more]

    From Institutional Investor: SPACs aren't dead. At least not to the folks at Cormorant Asset Management. The life sciences firm, whose hedge fund topped its peers in 2023, is confident it will match the success of its first blank-check company. Last week, the life sciences and biopharma speciali

  3. Benefit Street Partners closes fifth fund on $4.7 billion[more]

    Bailey McCann, Opalesque New York: Benefit Street Partners has closed its fifth flagship direct lending vehicle, BSP Debt Fund V, with $4.7 billion of investable capital across the strategy. Benefit Street invests primarily in privately originated, floating rate, senior secured loans. The fun

  4. 4 hedge fund themes that are working in 2024[more]

    From The Street: A poor earnings report from Tesla (TSLA) has not hurt the indexes on Thursday. The decline in Tesla stock, which is losing its position in the Magnificent Seven pantheon, is more than offset by strong earnings from IBM (IBM) and ServiceNow (NOW) . In addition, the much higher-t

  5. Opalesque Exclusive: A global macro fund eyes opportunities in bonds[more]

    Bailey McCann, Opalesque New York for New Managers: Munich-based ThirdYear Capital rebounded in 2023, following a tough year for global macro. The firm's flagship ART Global Macro strategy finished the year up 1